Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-...
Findings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023 Veracyte, Inc. VCYT announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast …